The use of non-financial performance metrics in determining directors’ remuneration: The case of listed companies in South Africa
African Journal of Business Ethics · 26.09.2023 · 17 (1) · 22-44
DOI: 10.15249/17-1-301 ↗Kurz gefasst
Fachartikel in der Zeitschrift African Journal of Business Ethics, online erschienen am 26.09.2023. Verfasst von Reon Matemane und 3 weiteren Autor:innen. Die Arbeit wurde bisher 6-mal zitiert (Crossref).
Abstract (Originalsprache)
Despite the increasing importance of environmental, social and governance (ESG) factors, it is not fully understood whether companies consider these factors when designing compensation plans for their directors. This study investigated the extent to which directors’ remuneration integrates ESG factors. The study sample is made up of JSE-listed companies for the period 2015 to 2021. The estimated generalised least squares regression technique was used to analyse the data. The results show the shift towards the integration of ESG factors in directors’ compensation plans. It should be established which ESG factors are pertinent in the South African context.
Zitieren
APA
Matemane, R., Moloi, T., Adelowotan, M., & Biswas, P. K. (2023). The use of non-financial performance metrics in determining directors’ remuneration: The case of listed companies in South Africa. African Journal of Business Ethics, 17(1), 22-44. https://doi.org/10.15249/17-1-301
Vancouver
Matemane R, Moloi T, Adelowotan M, Biswas PK. The use of non-financial performance metrics in determining directors’ remuneration: The case of listed companies in South Africa. African Journal of Business Ethics. 2023;17(1):22-44. doi:10.15249/17-1-301
BibTeX
@article{Matemane2023,
author = {Matemane, Reon and Moloi, Tankiso and Adelowotan, Michael and Biswas, Pallab Kumar},
title = {The use of non-financial performance metrics in determining directors’ remuneration: The case of listed companies in South Africa},
journal = {African Journal of Business Ethics},
year = {2023},
volume = {17},
number = {1},
pages = {22--44},
doi = {10.15249/17-1-301}
}
EUVIMED